Erythropoietin (EPO) is primarily indicated for patients suffering with Chronic Renal Failure (CRF), a condition where patients suffer from anemia due impaired production of EPO and the resulting deficiency of EPO.

Gennova launched a biosimilar recombinant EPO, made in CHO cells, under the brand name Vintor^® for intravenous or subcutaneous administration in 2007. Vintor is presented in different formulations as Vintor^® -2000, -3000, -4000, -6000, -10000 and 20000 IU containing EPO concentrated solution Ph. Eur. 2000, 3000, 4000, 6000, 10000 and 20000 IU, respectively.  Vintor^® is the market leader in India today (as per IMS) despite several competing brands being available in the country.